Traws Pharma Changes Certifying Accountant

TL;DR

Traws Pharma just switched accountants, filing an 8-K on 5/22/24.

AI Summary

Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on May 22, 2024, reporting a change in its certifying accountant as of May 17, 2024. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector.

Why It Matters

A change in a company's auditor can sometimes signal underlying financial concerns or a desire for a fresh perspective on financial reporting.

Risk Assessment

Risk Level: low — This filing solely reports a change in the company's accountant, which is a routine administrative event.

Key Players & Entities

• Traws Pharma, Inc. (company) — Registrant
• Onconova Therapeutics, Inc. (company) — Former company name
• May 17, 2024 (date) — Date of earliest event reported
• May 22, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation

FAQ

Filing Documents

• tm2415117d1_8k.htm (8-K) — 27KB
• tm2415117d1_ex16-1.htm (EX-16.1) — 3KB
• 0001104659-24-064340.txt ( ) — 199KB
• tmb-20240517.xsd (EX-101.SCH) — 3KB
• tmb-20240517_lab.xml (EX-101.LAB) — 33KB
• tmb-20240517_pre.xml (EX-101.PRE) — 22KB
• tm2415117d1_8k_htm.xml (XML) — 4KB

01

Item 4.01 Changes in Registrant's Certifying Accountant. On May 17, 2024, Ernst & Young LLP ("EY") notified Traws Pharma, Inc. (the "Company") that it declines to stand for reappointment as the Company's registered public accounting firm for the audit of the fiscal year ended December 31, 2024. Except as noted in the paragraph immediately below, the reports of EY on the Company's financial statements for the years ended December 31, 2023 and 2022 did not contain an adverse opinion or disclaimer of opinion, and such reports were not qualified or modified as to uncertainty, audit scope, or accounting principle. The audit reports of EY on the Company's financial statements as of and for the years ended December 31, 2023 and 2022 contained an explanatory paragraph which noted that the Company has suffered recurring losses from operations and there was substantial doubt as to the Company's ability to continue as a going concern. During the fiscal years ended December 31, 2023, and 2022, and the subsequent interim period through May 17, 2024, there were: (i) no "disagreements" within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions between the Company and EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to EY's satisfaction, would have caused EY to make reference to them in its reports; and (ii) no "reportable events" within the meaning of

(a)(1)(v) of Regulation S-K

Item 304(a)(1)(v) of Regulation S-K. The Company provided EY with a copy of the disclosures the Company is making in this Current Report on Form 8-K and requested that EY furnish a letter to the Company addressed to the Securities and Exchange Commission stating whether it agrees with the statements made herein. A copy of EY's letter, stating its agreement with such statements, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Exhibit 16.1 Letter of EY 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 22, 2024 TRAWS PHARMA, INC. By: /s/ MARK GUERIN Name: Mark Guerin Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR